This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ojwang, J. O.
Right arrow Articles by Wallace, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ojwang, J. O.
Right arrow Articles by Wallace, T. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Nov 1995, 2426-2435, Vol 39, No. 11
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1

JO Ojwang, RW Buckheit, Y Pommier, A Mazumder, K De Vreese, JA Este, D Reymen, LA Pallansch, C Lackman-Smith and TL Wallace
Triplex Pharmaceutical Corporation, The Woodlands, Texas 77380, USA.

T30177, an oligonucleotide composed of only deoxyguanosine and thymidine, is 17 nucleotides in length and contains single phosphorothioate internucleoside linkages at its 5' and 3' ends for stability. This oligonucleotide does not share significant primary sequence homology with or possess any complementary (antisense) sequence motifs to the human immunodeficiency virus type 1 (HIV-1) genome. T30177 inhibited replication of multiple laboratory strains of HIV-1 in human T-cell lines, peripheral blood lymphocytes, and macrophages. T30177 was also found to be capable of inhibiting multiple clinical isolates of HIV-1 and preventing the cytopathic effect of HIV- 1 in primary CD4+ T lymphocytes. In assays with human peripheral blood lymphocytes there was no observable toxicity associated with T30177 at the highest concentration tested (100 microM), while the median inhibitory concentration was determined to be in the range of 0.1 to 1.0 microM for the clinical isolates tested, resulting in a high therapeutic index for this drug. In temporal studies, the kinetics of addition of T30177 to infected cell cultures indicated that, like the known viral adsorption blocking agents dextran sulfate and Chicago sky blue, T30177 needed to be added to cells during or very soon after viral infection. However, analysis of nucleic acids extracted at 12 h postinfection from cells treated with T30177 at the time of virus infection established the presence of unintegrated viral cDNA, including circular proviral DNA, in the treated cells. In vitro analysis of viral enzymes revealed that T30177 was a potent inhibitor of HIV-1 integrase, reducing enzymatic activity by 50% at concentrations in the range of 0.050 to 0.09 microM. T30177 was also able to inhibit viral reverse transcriptase activity; however, the 50% inhibitory value obtained was in the range of 1 to 10 microM, depending on the template used in the enzymatic assay. No observable inhibition of viral protease was detected at the highest concentration of T30177 used (10 microM). In experiments in which T30177 was removed from infected cell cultures at 4 days post-HIV-1 infection, total suppression of virus production was observed for more than 27 days. PCR analysis of DNA extracted from cells treated in this fashion was unable to detect the presence of viral DNA 11 days after removal of the drug from the infected cell cultures. The ability of T30177 to inhibit both laboratory and clinical isolates of HIV-1 and the experimental data which suggest that T30177 represents a novel class of integrase inhibitors indicate that this compound is a viable candidate for evaluation as a therapeutic agent against HIV-1 in humans.


This article has been cited by other articles:

  • Hombrouck, A., Hantson, A., van Remoortel, B., Michiels, M., Vercammen, J., Rhodes, D., Tetz, V., Engelborghs, Y., Christ, F., Debyser, Z., Witvrouw, M. (2007). Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action. J Antimicrob Chemother 59: 1084-1095 [Abstract] [Full Text]  
  • Daelemans, D., Lu, R., De Clercq, E., Engelman, A. (2007). Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors. J. Virol. 81: 4381-4385 [Abstract] [Full Text]  
  • Cara, A., Klotman, M. E. (2006). Retroviral E-DNA: persistence and gene expression in nondividing immune cells. J. Leukoc. Biol. 80: 1013-1017 [Abstract] [Full Text]  
  • Bona, R., Andreotti, M., Buffa, V., Leone, P., Galluzzo, C. M., Amici, R., Palmisano, L., Mancini, M. G., Michelini, Z., Di Santo, R., Costi, R., Roux, A., Pommier, Y., Marchand, C., Vella, S., Cara, A. (2006). Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.. Antimicrob. Agents Chemother. 50: 3407-3417 [Abstract] [Full Text]  
  • Rando, R. F., Obara, S., Osterling, M. C., Mankowski, M., Miller, S. R., Ferguson, M. L., Krebs, F. C., Wigdahl, B., Labib, M., Kokubo, H. (2006). Critical design features of phenyl carboxylate-containing polymer microbicides.. Antimicrob. Agents Chemother. 50: 3081-3089 [Abstract] [Full Text]  
  • Shogan, B., Kruse, L., Mulamba, G. B., Hu, A., Coen, D. M. (2006). Virucidal Activity of a GT-Rich Oligonucleotide against Herpes Simplex Virus Mediated by Glycoprotein B.. J. Virol. 80: 4740-4747 [Abstract] [Full Text]  
  • Lee, D.-S., Jung, K.-E., Yoon, C.-H., Lim, H., Bae, Y.-S. (2005). Newly Designed Six-Membered Azasugar Nucleotide-Containing Phosphorothioate Oligonucleotides as Potent Human Immunodeficiency Virus Type 1 Inhibitors. Antimicrob. Agents Chemother. 49: 4110-4120 [Abstract] [Full Text]  
  • Fikkert, V., Van Maele, B., Vercammen, J., Hantson, A., Van Remoortel, B., Michiels, M., Gurnari, C., Pannecouque, C., De Maeyer, M., Engelborghs, Y., De Clercq, E., Debyser, Z., Witvrouw, M. (2003). Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations. J. Virol. 77: 11459-11470 [Abstract] [Full Text]  
  • Vandegraaff, N., Kumar, R., Hocking, H., Burke, T. R. Jr., Mills, J., Rhodes, D., Burrell, C. J., Li, P. (2001). Specific Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Integration in Cell Culture: Putative Inhibitors of HIV-1 Integrase. Antimicrob. Agents Chemother. 45: 2510-2516 [Abstract] [Full Text]  
  • Bedard, J., May, S., L'Heureux, L., Stamminger, T., Copsey, A., Drach, J., Huffman, J., Chan, L., Jin, H., Rando, R. F. (2000). Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus. Antimicrob. Agents Chemother. 44: 929-937 [Abstract] [Full Text]  
  • Wallace, T. L., Gamba-Vitalo, C., Loveday, K. S., Cossum, P. A. (2000). Acute, Multiple-Dose, and Genetic Toxicology of AR177, an Anti-HIV Oligonucleotide. Toxicol Sci 53: 63-70 [Abstract] [Full Text]  
  • de Muys, J.-M., Gourdeau, H., Nguyen-Ba, N., Taylor, D. L., Ahmed, P. S., Mansour, T., Locas, C., Richard, N., Wainberg, M. A., Rando, R. F. (1999). Anti-Human Immunodeficiency Virus Type 1 Activity, Intracellular Metabolism, and Pharmacokinetic Evaluation of 2'-Deoxy-3'-Oxa-4'-Thiocytidine. Antimicrob. Agents Chemother. 43: 1835-1844 [Abstract] [Full Text]  
  • King, P. J., Robinson, W. E. Jr. (1998). Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compound L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase. J. Virol. 72: 8420-8424 [Abstract] [Full Text]  
  • Schols, D., Este, J. A., Cabrera, C., De Clercq, E. (1998). T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1alpha Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use. J. Virol. 72: 4032-4037 [Abstract] [Full Text]  
  • Esté, J. A., Cabrera, C., Schols, D., Cherepanov, P., Gutierrez, A., Witvrouw, M., Pannecouque, C., Debyser, Z., Rando, R. F., Clotet, B., Desmyter, J., De Clercq, E. (1998). Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Mol. Pharmacol. 53: 340-345 [Abstract] [Full Text]  
  • Cherepanov, P., Esté, J. A., Rando, R. F., Ojwang, J. O., Reekmans, G., Steinfeld, R., David, G., De Clercq, E., Debyser, Z. (1997). Mode of Interaction of G-Quartets with the Integrase of Human Immunodeficiency Virus Type 1. Mol. Pharmacol. 52: 771-780 [Abstract] [Full Text]  
  • Esté, J. A., Schols, D., De Vreese, K., Van Laethem, K., Vandamme, A.-M., Desmyter, J., De Clercq, E. (1997). Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 Glycoprotein. Mol. Pharmacol. 52: 98-104 [Abstract] [Full Text]  
  • Wallace, T. L., Bazemore, S. A., Holm, K., Markham, P. M., Shea, J. P., Chaudhary, N., Cossum, P. A. (1997). Pharmacokinetics and Distribution of a 33P-labeled Anti-Human Immunodeficiency Virus Oligonucleotide (AR177) after Single- and Multiple-Dose Intravenous Administration to Rats. J. Pharmacol. Exp. Ther. 280: 1480-1488 [Abstract] [Full Text]  
  • Mazumder, A., Neamati, N., Pilon, A. A., Sunder, S., Pommier, Y. (1996). Chemical Trapping of Ternary Complexes of Human Immunodeficiency Virus Type 1Integrase, Divalent Metal, and DNA Substrates Containing an Abasic Site. IMPLICATIONS FOR THE ROLE OF LYSINE 136IN DNA BINDING. J. Biol. Chem. 271: 27330-27338 [Abstract] [Full Text]  
  • Bishop, J. S., Guy-Caffey, J. K., Ojwang, J. O., Smith, S. R., Hogan, M. E., Cossum, P. A., Rando, R. F., Chaudhary, N. (1996). Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide. J. Biol. Chem. 271: 5698-5703 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»